一位在接受全剂量直接口服抗凝药物治疗后从 COVID19 中康复的患者中出现了肺栓塞复发的意外病例。
An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug.
机构信息
Cardiovascular Department, Hospital Papa Giovanni XXIII, Piazza OMS 1, Bergamo, Italy.
Department of Medicine and Surgery, University of Milan, Milan, Italy.
出版信息
BMC Pulm Med. 2021 Mar 24;21(1):102. doi: 10.1186/s12890-021-01453-2.
BACKGROUND
Coronavirus Disease 2019 (COVID-19) is a pandemic affecting all countries in the world. Italy has been particularly afflicted by the health emergency, and since the peak phase has passed, major concern regarding medium to long term complications due to COVID-19 is arising. Little is known in literature regarding thromboembolic complications once healed after COVID-19.
CASE PRESENTATION
A 51-year-old patient recovered from COVID-19 pneumonia complicated by pulmonary embolism (PE) came to the hospital for palpitations and chest pain. Although he was on treatment dose of direct oral anticoagulation (DOAC), massive recurrent PE was diagnosed.
CONCLUSION
In the early post COVID-19 era, the question remains regarding the efficacy of DOACs in COVID-19 patients.
背景
2019 年冠状病毒病（COVID-19）是一种影响世界各国的大流行病。意大利特别受到卫生紧急情况的影响，自高峰期以来，人们越来越关注 COVID-19 引起的中远期并发症。文献中对于 COVID-19 痊愈后的血栓栓塞并发症知之甚少。
病例介绍
一位 51 岁的患者从 COVID-19 肺炎合并肺栓塞（PE）中康复后来医院就诊，出现心悸和胸痛。尽管他正在接受直接口服抗凝剂（DOAC）的治疗剂量，但仍被诊断出患有大量复发性 PE。
结论
在 COVID-19 后早期，DOAC 在 COVID-19 患者中的疗效仍然存在疑问。
Zotero 插件